<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0121-0793</journal-id>
<journal-title><![CDATA[Iatreia]]></journal-title>
<abbrev-journal-title><![CDATA[Iatreia]]></abbrev-journal-title>
<issn>0121-0793</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Antioquia]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0121-07932018000100029</article-id>
<article-id pub-id-type="doi">10.17533/udea.iatreia.v31n1a03</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Terapia anti-angiogénica con ranibizumab en el tratamiento de retinopatía de la prematuridad]]></article-title>
<article-title xml:lang="en"><![CDATA[Intravitreal ranibizumab injections in patients with retinopathy of prematurity (ROP)]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Zuluaga-Gómez]]></surname>
<given-names><![CDATA[Liliana María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Montoya-López]]></surname>
<given-names><![CDATA[Laura]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Donado-Gómez]]></surname>
<given-names><![CDATA[Jorge Hernando]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Pontificia Bolivariana Departamento de retina ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Pontificia Bolivariana  ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Pablo Tobón Uribe Departamento de docencia ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2018</year>
</pub-date>
<volume>31</volume>
<numero>1</numero>
<fpage>29</fpage>
<lpage>35</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0121-07932018000100029&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0121-07932018000100029&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0121-07932018000100029&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Objetivo:  describir los desenlaces luego de la aplicación de terapia antiangiogénica intravítrea con Ranibizumab en pacientes con retinopatía de la prematuridad (ROP), tratados inicialmente con termoterapia transpupilar láser sin regresión de la enfermedad.  Métodos:  cohorte histórica en Clínica Universitaria Bolivariana (CUB) durante 2008-2015. Evaluación de pacientes prematuros con retinopatía agresiva posterior y enfermedad umbral que recibieron termoterapia transpupilar láser como tratamiento inicial. Debido a que continuaba el proceso de neovascularización, se indicó terapia antiangiogénica intravítrea con ranibizumb. El desenlace primario fue la resolución de la neovascularización (NV) y la ausencia de recurrencia. Los desenlaces secundarios fueron agudeza visual y complicaciones oculares y sistémicas.  Resultados:  ocho ojos de 4 pacientes fueron incluidos. Se encontró resolución de la neovascularización en 6 de los 8 ojos, densidad de incidencia 48 x 100 personas año, IC 95 % = 17,6 - 100 con una mediana de seguimiento de 23.5 meses, rango 13-90 meses. No se encontraron complicaciones oculares ni sistémicas.  Conclusión:  esta pequeña cohorte sugiere que la inyección intravitrea de ranibizumab para ROP, en casos que inicialmente se trataron con termoterapia transpupilar con láser y no se resolvió la retinopatía, ayudaría como complemento para una evolución favorable.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[SUMMARY  Purpose:  To describe ocular outcomes after intravitreal ranibizumab injections in patients with retinopathy of prematurity (ROP), who had transpupillary laser thermotherapy without regression of the disease.  Methods:  Historical cohort in Clínica Universitaria Bolivariana (CUB) during 2008-2015. Evaluation of patients with aggressive posterior ROP, threshold disease, who received intravitreal ranibizumab secondary to treatment with transpupillary thermotherapy. The primary outcome was treatment success defined as the resolution of neovascularization (NV) and no recurrence. The secondary endpoints were visual acuity and ocular and systemic complications.  Results:  Eight eyes of four patients were included in the study. Six eyes had resolution of retinopathy, Incidence density 48 x 100 person years, 95 % CI = 17.6 - 100 with a median follow-up of 23.5 months, range 13-90 months. No ocular or systemic complications associated with the procedure was found.  Conclusion:  This cohort suggests that intravitreal injection of ranibizumab for ROP in refractory laser photocoagulation cases, results in apparent ocular preservation a long-term the outcome.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Antiangiogénicos]]></kwd>
<kwd lng="es"><![CDATA[Inyección Intravítrea]]></kwd>
<kwd lng="es"><![CDATA[Retinopatía del Prematuro (ROP)]]></kwd>
<kwd lng="en"><![CDATA[Antiangiogenics]]></kwd>
<kwd lng="en"><![CDATA[Intravitreal Injections]]></kwd>
<kwd lng="en"><![CDATA[Retinopathy of Prematurity]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Clark]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Mandal]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of retinopathy of prematurity]]></article-title>
<source><![CDATA[Early Hum Dev]]></source>
<year>2008</year>
<volume>84</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>95-9</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gergely]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Gerinec]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Retinopathy of prematurity-epidemics, incidence, prevalence, blindness]]></article-title>
<source><![CDATA[Bratisl Lek Listy]]></source>
<year>2010</year>
<volume>111</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>514-7</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giraldo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hurtado]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Donado]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Molina]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiología de la retinopatía del prematuro en Medellín, 2003-2008]]></article-title>
<source><![CDATA[Iatreia]]></source>
<year>2011</year>
<volume>24</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>250-8</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The increasing problem of retinopathy of prematurity]]></article-title>
<source><![CDATA[J Comm Eye Health]]></source>
<year>2001</year>
<volume>14</volume>
<numero>40</numero>
<issue>40</issue>
<page-range>58-9</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castellanos]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Schwartz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[García-Aguirre]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Quiroz-Mercado]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity]]></article-title>
<source><![CDATA[Br J Ophthalmol]]></source>
<year>2013</year>
<volume>97</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>816-9</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stenson]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Tarnow-Mordi]]></surname>
<given-names><![CDATA[WO]]></given-names>
</name>
<name>
<surname><![CDATA[Darlow]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
</person-group>
<collab>BOOST II United Kingdom Collaborative Group; BOOST II Australia Collaborative Group; BOOST II New Zealand Collaborative Group</collab>
<article-title xml:lang=""><![CDATA[Oxygen saturation and outcomes in preterm infants]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2013</year>
<volume>368</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>2094-104</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hartnett]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Penn]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mechanisms and management of retinopathy of prematurity]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2012</year>
<volume>367</volume>
<numero>26</numero>
<issue>26</issue>
<page-range>2515-26</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O&#8217;Keefe]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kirwan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Screening for retinopathy of prematurity]]></article-title>
<source><![CDATA[Early Hum Dev]]></source>
<year>2008</year>
<volume>84</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>89-94</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eltzschig]]></surname>
<given-names><![CDATA[HK]]></given-names>
</name>
<name>
<surname><![CDATA[Carmeliet]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypoxia and inflammation]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2011</year>
<volume>364</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>656-65</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Good]]></surname>
<given-names><![CDATA[WV]]></given-names>
</name>
</person-group>
<collab>Early Treatment for Retinopathy of Prematurity Cooperative Group</collab>
<article-title xml:lang=""><![CDATA[Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial]]></article-title>
<source><![CDATA[Trans Am Ophthalmol Soc]]></source>
<year>2004</year>
<volume>102</volume>
<page-range>233-48</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<collab>International Committee for the Classification of Retinopathy of Prematurity</collab>
<article-title xml:lang=""><![CDATA[The International Classification of Retinopathy of Prematurity revisited]]></article-title>
<source><![CDATA[Arch Ophthalmol]]></source>
<year>2005</year>
<volume>123</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>991-9</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<source><![CDATA[Guía de práctica clínica del recién nacido prematuro - 2013 Guía No. 04]]></source>
<year>2013</year>
<publisher-loc><![CDATA[Bogotá ]]></publisher-loc>
<publisher-name><![CDATA[Ministerio de Salud y Protección Social - Colciencias]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mintz-Hittner]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[Kennedy]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Chuang]]></surname>
<given-names><![CDATA[AZ]]></given-names>
</name>
</person-group>
<collab>BEAT-ROP Cooperative Group</collab>
<article-title xml:lang=""><![CDATA[Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2011</year>
<volume>364</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>603-15</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Menke]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[Framme]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Nelle]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Berger]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Sturm]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Wolf]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease]]></article-title>
<source><![CDATA[BMC Ophthalmol]]></source>
<year>2015</year>
<volume>15</volume>
<page-range>20</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jabs]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Improving the reporting of clinical case series]]></article-title>
<source><![CDATA[Am J Ophthalmol]]></source>
<year>2005</year>
<volume>139</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>900-5</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arámbulo]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Dib]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Iturralde]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Duran]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Brito]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fortes Filho]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intravitreal ranibizumab as a primary or a combined treatment for severe retinopathy of prematurity]]></article-title>
<source><![CDATA[Clin Ophthalmol]]></source>
<year>2015</year>
<volume>9</volume>
<page-range>2027-32</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Erol]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Coban]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
<name>
<surname><![CDATA[Sari]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Bilgin]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Dogan]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Ozdemir]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity]]></article-title>
<source><![CDATA[Arq Bras Oftalmol]]></source>
<year>2015</year>
<volume>78</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>340-3</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yi]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Su]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ye]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of Intravitreal Ranibizumab in the Treatment of Retinopathy of Prematurity in Chinese Infants]]></article-title>
<source><![CDATA[Curr Eye Res]]></source>
<year>2016</year>
<volume>41</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1092-7</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Menke]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[Framme]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Nelle]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Berger]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Sturm]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Wolf]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease]]></article-title>
<source><![CDATA[BMC Ophthalmol]]></source>
<year>2015</year>
<volume>15</volume>
<page-range>20</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mintz-Hittner]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[Geloneck]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Review of effects of anti-VEGF treatment on refractive error]]></article-title>
<source><![CDATA[Eye Brain]]></source>
<year>2016</year>
<volume>8</volume>
<page-range>135-40</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jang]]></surname>
<given-names><![CDATA[SY]]></given-names>
</name>
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Delayed-onset retinal detachment after an intravitreal injection of ranibizumab for zone 1 plus retinopathy of prematurity]]></article-title>
<source><![CDATA[J AAPOS]]></source>
<year>2010</year>
<volume>14</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>457-9</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Honda]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hirabayashi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Tsukahara]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Negi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity]]></article-title>
<source><![CDATA[Graefes Arch Clin Exp Ophthalmol]]></source>
<year>2008</year>
<volume>246</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1061-3</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mota]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Carneiro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Breda]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rosas]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Magalhães]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Combination of intravitreal ranibizumab and laser photocoagulation for aggressive posterior retinopathy of prematurity]]></article-title>
<source><![CDATA[Case Rep Ophthalmol]]></source>
<year>2012</year>
<volume>3</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>136-41</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baumal]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Goldberg]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Fein]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primary intravitreal ranibizumab for high-risk retinopathy of prematurity]]></article-title>
<source><![CDATA[Ophthalmic Surg Lasers Imaging Retina]]></source>
<year>2015</year>
<volume>46</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>432-8</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
